KALA Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect 眼科查看全文
發仔说美股2022-12-30 17:30
【美股盘前 | 药品制造商Kala续涨超6%,Wedbush予其47美元目标价】
华盛资讯12月30日消息,美股盘前,三大期指走弱,截至发稿,纳指期货跌0.61%,标普500指数期货跌0.45%,道指期货跌0.32%。
药物制造商Kala Pharmaceuticals盘前上涨6.68%,近两个交易日涨逾317%,Wedbush分析师Andreas Ar...查看全文
一周一次的见面会又来了,还是我→美股风向标。致力于追踪热门美股优质标的,挖掘更多投资机会。接下来我们来看看本周有哪些重要的标的可以关注吧! 1、Kala制药公司 $KALA 表示,FDA接受了其主要候选产品KPI-012——治疗眼睛罕见疾病的研究... 网页链接
智通财经APP获悉,专注于眼部护理的全球医疗专业公司爱尔康(ALC.US)宣布,同意从生物制药公司Kala Pharma(KALA.US)手中收购EYSUVIS(0.25%氯替泼诺混悬滴眼液)和INVELTYS(1%氯替泼诺混悬滴眼液)。 据了解,EYSUVIS是首个也是唯一一个获FD... 网页链接
$Kala Pharmaceuticals, Inc.(KALA)$ 8-K - Current report Filed: 2018-03-05 AccNo: 0001104659-18-014618 Size: 25 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers http:/...
$Kala Pharmaceuticals, Inc.(KALA)$ 内部交易: 2018-02-28,Chief Scientific Officer,Chen Hongming ,期权,9769普通股, $2.26
$Kala Pharmaceuticals, Inc.(KALA)$ SC 13D - General statement of acquisition of beneficial ownership Filed: 2018-02-14 AccNo: 0001144204-18-009020 Size: 92 KB 网页链接
$Kala Pharmaceuticals, Inc.(KALA)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-13 AccNo: 0001193125-18-042519 Size: 136 KB 网页链接
$Kala Pharmaceuticals, Inc.(KALA)$ 内部交易: 2018-02-08,10% Owner,ORBIMED ADVISORS LLC ,买入,25000普通股, $12.93
$Kala Pharmaceuticals, Inc.(KALA)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-12 AccNo: 0001144204-18-007325 Size: 96 KB 网页链接
$Kala Pharmaceuticals, Inc.(KALA)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-08 AccNo: 0000902219-18-000322 Size: 37 KB 网页链接
$Kala Pharmaceuticals, Inc.(KALA)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-07 AccNo: 0001193125-18-034854 Size: 130 KB 网页链接
$Kala Pharmaceuticals, Inc.(KALA)$ 内部交易: 2018-02-02,10% Owner,ORBIMED ADVISORS LLC ,买入,37840普通股, $14.73
$Kala Pharmaceuticals, Inc.(KALA)$ 内部交易: 2018-02-01,10% Owner,ORBIMED ADVISORS LLC ,买入,22840普通股, $14.99